Inhibition of DNAM-1, a critical new genetic factor in autoimmune disorders, does not prevent the development of CIA, despite its efficacy in other models of inflammatory diseases, such as bleomycin-induced fibrosis, encephalomyelitis and GVHD. This evidence concerns the gene CD226 and Autoimmunity.